Trials / Active Not Recruiting
Active Not RecruitingNCT06952465
A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
A Cohort Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis Using Administrative Health Claims Database
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,000 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to further evaluate the safety of deucravacitinib treatment in Japanese patients with psoriasis in the real-world setting
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deucravacitinib | As per product label |
| BIOLOGICAL | Any biologic treatment for psoriasis | According to the product label |
Timeline
- Start date
- 2025-01-24
- Primary completion
- 2031-11-30
- Completion
- 2031-11-30
- First posted
- 2025-05-01
- Last updated
- 2025-05-01
Locations
2 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06952465. Inclusion in this directory is not an endorsement.